# US 2008/0305115 A1 · Reduced-mass, long-acting dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305115 A1
- Document ID: US20080305115A1
- Status: Published application
- Kind: A1
- Application number: 12/157,368
- Filed: 2008-06-09
- Published: 2008-12-11
- Earliest claimed: 2007-06-07
- Inventors: Thomas R. Tice; Peter Markland; Jay K. Staas
- Web page: https://patentgrep.com/patent/US20080305115A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions are disclosed whereby free antibody or nucleic acid co-administered with a long-acting formulation, such as a microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release. One result is that less of the long-acting formulation excipient or polymer is needed allowing for small-volume administrations as required, for example, for ocular, intra-dermal, orthopedic, brain and spinal delivery. In one aspect, the free antibody or nucleic acid alone has efficacy for an extended period, during which time, very little or no long-acting formulation antibody or nucleic acid is released. In one aspect, after the free antibody or nucleic acid has diminished activity, is gone, or no longer has activity, the long-acting formulation antibody or nucleic acid begins to release for a desired preprogrammed duration to provide long-acting durations. Less formulation mass is needed because the entire antibody or nucleic acid is not encapsulated or implanted with encapsulation or implant excipient or polymer. In addition, more antibody or nucleic acid can be administered to afford longer-acting formulations.

## Claims

### Claim 1

A method of extending the release profile of an antibody or nucleic acid in a subject while reducing the total system mass of the polymer material of a biodegradable, long-acting formulation comprising administering to the subject at about the same time a free antibody or nucleic acid and a biodegradable, long-acting formulation containing the antibody or nucleic acid, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least a week and wherein the biodegradable, long-acting formulation releases its antibody or nucleic acid to coincide with the diminution of activity of the free antibody or nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the free antibody or nucleic acid and the long acting formulation are part of one unitary formulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administration is to a local delivery site.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administration is an ocular administration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration is an interarticular administration.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administration is to the central nervous system.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administration is to a tumor.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administration is an intradermal administration.

### Claim 9 (depends on 1)

The method of claim 1, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least two weeks.

### Claim 10 (depends on 1)

The method of claim 1, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least three weeks.

### Claim 11 (depends on 1)

The method of claim 1, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least four weeks.

### Claim 12 (depends on 1)

The method of claim 1, wherein the biodegradable, long-acting formulation comprises a microparticle.

### Claim 13 (depends on 1)

The method of claim 1, wherein the biodegradable, long-acting formulation comprises an implant.

### Claim 14 (depends on 1)

The method of claim 1, wherein the antibody or nucleic acid comprises an antibody that specifically binds tumor necrosis factor-alpha (TNFα), vascular endothelial growth factor-A (VEGF-A), CD20, α4-integrin, or beta-amyloid.

### Claim 15 (depends on 1)

The method of claim 1, wherein the antibody or nucleic acid comprises a small interfering RNA (siRNA) or antisense oligonucleotide.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 17

A controlled release formulation comprising a free antibody or nucleic acid and a biodegradable, long-acting formulation containing the antibody or nucleic acid, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least a week and wherein the biodegradable, long acting formulation releases its antibody or nucleic acid to coincide with the diminution of activity of the free antibody or nucleic acid.

### Claim 18 (depends on 17)

The controlled release formulation of claim 17, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least two weeks.

### Claim 19 (depends on 17)

The controlled release formulation of claim 17, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least three weeks.

### Claim 20 (depends on 17)

The controlled release formulation of claim 17, wherein the free antibody or nucleic acid has a pharmaceutically acceptable bioactivity period of at least four weeks.

### Claim 21 (depends on 17)

The controlled release formulation of claim 17, wherein the biodegradable, long-acting formulation comprises a microparticle.

### Claim 22 (depends on 17)

The controlled release formulation of claim 17, wherein the biodegradable, long-acting formulation comprises an implant.

### Claim 23 (depends on 17)

The controlled release formulation of claim 17, wherein the free antibody or nucleic acid and the long acting formulation are part of one unitary formulation.

### Claim 24 (depends on 17)

The controlled release formulation of claim 17, wherein (1) the free antibody or nucleic acid and (2) the long acting formulation are separately contained in a kit.

### Claim 25 (depends on 17)

The controlled release formulation of claim 17, wherein the antibody or nucleic acid comprises an antibody that specifically binds tumor necrosis factor-alpha (TNFα), vascular endothelial growth factor-A (VEGF-A), CD20, α4-integrin, or beta-amyloid.

### Claim 26 (depends on 17)

The controlled release formulation of claim 17, wherein the antibody or nucleic acid comprises a small interfering RNA (siRNA) or antisense oligonucleotide.
